Looking Forward

We are looking forward to advancing our programs in CAR-T and in gene therapies, including an off-the-shelf allogeneic CAR-T in BCMA and another in MUC1C, our first solid tumor product candidate with multiple potential targets. In addition to our pipeline of CAR-T product candidates across liquid and solid tumors, we are focused on developing gene therapies to treat rare diseases.